Inventor · disambiguated record
Jonathan William Bourne
Also filed as: BOURNE JONATHAN W · BOURNE JONATHAN WILLIAM
16 granted patents·7 pending applications·48 citations·filing 2013–2024
91Inventor score
Files withSRX CARDIO LLC18BIRCHBIOMED INC2NEW YORK SOC RUPTURED & CRIPPLED MAINTAINING HOSPITAL FOR SPECIAL SURGERY2PORTOLA PHARM INC1
Top patents by PatentIndex Score
23 records- 0195US10980801B2Phenylpiperazine proprotein convertase subtilisin/kexin type 9 (PCSK9) modulators and their useSRX CARDIO LLC·Filed 2020·Granted Apr 20, 2021·6 cites·15 claims
- 0294US10688114B2Composition and methods of use of small molecules as binding ligands for the modulation of proprotein convertase subtilisin/kexin type 9(PCSK9) protein activitySRX CARDIO LLC·Filed 2019·Granted Jun 23, 2020·5 cites·15 claims
- 0392US10865185B2Composition and methods of use of tetrahydroisoquinoline small molecules to bind and modulate PCSK9 protein activitySRX CARDIO LLC·Filed 2016·Granted Dec 15, 2020·5 cites·8 claims
- 0492US10568882B2Phenylpiperazine proprotein convertase subtilisin/kexin type 9 (PCSK9) modulators and their useSRX CARDIO LLC·Filed 2016·Granted Feb 25, 2020·6 cites·13 claims
- 0592US10287317B2Proprotein convertase subtilisin kexin type 9 (PCSK9) allosteric binding ligands to modulate serum low density lipoprotein (LDL) levelsSRX CARDIO LLC·Filed 2015·Granted May 14, 2019·12 cites·28 claims
- 0689US10821106B2Composition and methods of use of novel phenylalanine small organic compounds to directly modulate PCSK9 protein activitySRX CARDIO LLC·Filed 2016·Granted Nov 3, 2020·4 cites·11 claims
- 0789US10307433B2Composition and methods of use of small molecules as binding ligands for the modulation of proprotein convertase subtilisin/kexin type 9(PCSK9) protein activitySRX CARDIO LLC·Filed 2018·Granted Jun 4, 2019·5 cites·20 claims
- 0888US10034892B2Composition and methods of use of small molecules as binding ligands for the modulation of proprotein convertase subtilisin/kexin type 9(PCSK9) protein activitySRX CARDIO LLC·Filed 2015·Granted Jul 31, 2018·5 cites·24 claims
- 0985US2024122951A1Method to treat lipid dysregulation by modulating activity of proprotein convertase subtilisin/kexin type 9 (pcsk9) protein with small molecule ligandsSRX CARDIO LLC·Filed 2023·Application pending·0 cites
- 1080US2024415830A1Composition and methods of use of novel phenylalanine small organic compounds to directly modulate pcsk9 protein activitySRX CARDIO LLC·Filed 2024·Application pending·0 cites
- 1178US11771710B2Method to treat lipid dysregulation by modulation of proprotein convertase subtilisin/kexin type 9 (PCSK9) protein activity with small molecule ligandsSRX CARDIO LLC·Filed 2021·Granted Oct 3, 2023·0 cites·13 claims
- 1273US11026957B2Method to treat lipid dysregulation by modulation of proprotein convertase subtilisin/kexin type 9 (PCSK9) protein activity with small molecule ligandsSRX CARDIO LLC·Filed 2020·Granted Jun 8, 2021·0 cites·15 claims
- 1373US2025255792A1Methods of Using a Small Molecule Chemical Compound to Reduce the Appearance of Rhytids and WrinklesBIRCHBIOMED INC·Filed 2023·Application pending·0 cites
- 1470US11925637B2Phenylpiperazine proprotein convertase subtilisin/kexin type 9 (PCSK9) modulators and their useSRX CARDIO LLC·Filed 2021·Granted Mar 12, 2024·0 cites·17 claims
- 1569US11944619B2Phenylalanine small organic compounds to directly modulate PCSK9 protein activitySRX CARDIO LLC·Filed 2020·Granted Apr 2, 2024·0 cites·17 claims
- 1667US11945782B2Composition and methods of use of tetrahydroisoquinoline small molecules to bind and modulate PCSK9 protein activitySRX CARDIO LLC·Filed 2020·Granted Apr 2, 2024·0 cites·5 claims
- 1763US11891369B2Compounds for binding proprotein convertase subtilisin/kexin type 9SRX CARDIO LLC·Filed 2020·Granted Feb 6, 2024·0 cites·5 claims
- 1860US2024226085A1Kynrenine and derivatives thereof for treating atrophic scarringBIRCHBIOMED INC·Filed 2022·Application pending·0 cites
- 1954US12115154B2Compounds for the modulation of proprotein convertase subtilisin/kexin type 9 (PCSK9)SRX CARDIO LLC·Filed 2020·Granted Oct 15, 2024·0 cites·7 claims
- 2053US2019119236A1Compounds for binding proprotein convertase subtilisin/kexin type 9 (pcsk9)PORTOLA PHARM INC·Filed 2017·Application pending·0 cites
- 2151US9309304B2Glycation cross-link breakers to increase resistance to enzymatic degradationNEW YORK SOC RUPTURED & CRIPPLED MAINTAINING HOSPITAL FOR SPECIAL SURGERY·Filed 2013·Granted Apr 12, 2016·0 cites·10 claims
- 2251US2022267269A1Compounds for the modulation of proprotein convertase subtilisin/kexin type 9 (pcsk9)SRX CARDIO LLC·Filed 2020·Application pending·0 cites
- 2344US2016280764A1Glycation Cross-link Breakers to Increase Resistance to Enzymatic DegradationNEW YORK SOC RUPTURED & CRIPPLED MAINTAINING HOSPITAL FOR SPECIAL SURGERY·Filed 2016·Application pending·0 cites
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →